发明授权
US08148396B2 Triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors
有权
三唑并吡啶11-β羟基类固醇脱氢酶I型抑制剂
- 专利标题： Triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors
- 专利标题（中）： 三唑并吡啶11-β羟基类固醇脱氢酶I型抑制剂
-
申请号： US12424674申请日： 2009-04-16
-
公开(公告)号： US08148396B2公开(公告)日： 2012-04-03
- 发明人: James J. Li , Lawrence G. Hamann , Haixia Wang , Zheming Ruan , Christopher B. Cooper , Jun Li , Jeffrey A. Robl
- 申请人： James J. Li , Lawrence G. Hamann , Haixia Wang , Zheming Ruan , Christopher B. Cooper , Jun Li , Jeffrey A. Robl
- 申请人地址： US NJ Princeton
- 专利权人： Bristol-Myers Squibb Company
- 当前专利权人： Bristol-Myers Squibb Company
- 当前专利权人地址： US NJ Princeton
- 代理商 Terence J. Bogie
- 主分类号： A01N43/42
- IPC分类号： A01N43/42 ; A61K31/44 ; C07D513/02
摘要：
Novel compounds are provided which are 11-beta-hydroxysteroid dehydrogenase type I inhibitors. 11-beta-hydroxysteroid dehydrogenase type I inhibitors are useful in treating, preventing, or slowing the progression of diseases requiring 11-beta-hydroxysteroid dehydrogenase type I inhibitor therapy. These novel compounds have the structure: or stereoisomers or prodrugs or pharmaceutically acceptable salts thereof wherein W, L, R3, R3a, R3b and R4 are defined herein.
公开/授权文献
信息查询
IPC分类:
